Advaxis Company Profile (NASDAQ:ADXS)

About Advaxis

Advaxis logoAdvaxis, Inc. is a clinical-stage biotechnology company. The Company's immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies. The Company's immunotherapy candidates include Axalimogene filolisbac, ADXS-PSA and ADXS-HER2. Axalimogene filolisbac (ADXS-HPV) is a lead Lm-LLO immunotherapy product candidate for the treatment of human papilloma virus (HPV) associated cancers. ADXS-PSA is an Lm-LLO immunotherapy product candidate designed to target the Prostate Specific Antigen (PSA) associated with prostate cancer. ADXS-HER2 is an Lm-LLO immunotherapy product candidate designed for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) expressing cancers, including human and canine osteosarcoma, breast, gastric and other cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADXS
  • CUSIP:
Key Metrics:
  • Previous Close: $13.35
  • 50 Day Moving Average: $10.68
  • 200 Day Moving Average: $8.76
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.27
  • P/E Growth: 0.00
  • Market Cap: $458.52M
  • Outstanding Shares: 34,346,000
  • Beta: 1.51
Additional Links:
Companies Related to Advaxis:

Analyst Ratings

Consensus Ratings for Advaxis (NASDAQ:ADXS) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.80 (93.26% upside)

Analysts' Ratings History for Advaxis (NASDAQ:ADXS)
Show:
DateFirmActionRatingPrice TargetDetails
8/5/2016HC WainwrightReiterated RatingBuy$23.00View Rating Details
8/4/2016Jefferies GroupReiterated RatingBuyView Rating Details
8/3/2016Barclays PLCBoost Price TargetOverweight$15.00 -> $20.00View Rating Details
7/7/2016FBR & CoReiterated RatingOutperform$34.00View Rating Details
12/17/2015Janney Montgomery ScottReiterated RatingBuy$22.00View Rating Details
9/11/2015GuggenheimInitiated CoverageBuy$30.00View Rating Details
6/26/2015MLV & Co.Initiated CoverageBuyView Rating Details
3/17/2015Noble FinancialReiterated RatingBuyView Rating Details
1/8/2015AegisReiterated RatingBuy -> PositiveView Rating Details
(Data available from 8/23/2014 forward)

Earnings

Earnings History for Advaxis (NASDAQ:ADXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/13/2016        
4/16/2015($0.31)($0.33)ViewN/AView Earnings Details
9/23/2014($0.25)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Advaxis (NASDAQ:ADXS)
Current Year EPS Consensus Estimate: $-1.85 EPS
Next Year EPS Consensus Estimate: $-2.13 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.61)($0.61)($0.61)
Q3 20161$0.55$0.55$0.55
Q4 20161($0.58)($0.58)($0.58)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Advaxis (NASDAQ:ADXS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Advaxis (NASDAQ:ADXS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2016David SidranskyDirectorSell22,808$15.01$342,348.08View SEC Filing  
8/8/2016Richard J BermanDirectorSell18,000$15.21$273,780.00View SEC Filing  
5/13/2016Thomas J MckearnDirectorSell4,100$7.45$30,545.00View SEC Filing  
5/2/2016Daniel O'connorCEOSell8,237$7.51$61,859.87View SEC Filing  
5/2/2016Robert PetitInsiderSell2,785$7.51$20,915.35View SEC Filing  
3/31/2016Robert PetitInsiderSell3,325$9.13$30,357.25View SEC Filing  
3/16/2016Thomas J MckearnDirectorSell14,000$8.25$115,500.00View SEC Filing  
2/24/2016Sara BonsteinCFOSell15,037$5.58$83,906.46View SEC Filing  
1/29/2016Daniel O'connorCEOSell8,818$6.88$60,667.84View SEC Filing  
1/29/2016Robert PetitinsiderSell3,099$6.88$21,321.12View SEC Filing  
10/26/2015Gregory T MayesCOOSell19,231$11.63$223,656.53View SEC Filing  
10/20/2015David J MauroInsiderSell24,586$10.08$247,826.88View SEC Filing  
8/24/2015Adage Capital Partners Gp LlcMajor ShareholderBuy300,000$14.15$4,245,000.00View SEC Filing  
4/30/2015Adage Capital Partners Gp LlcMajor ShareholderBuy500,000$19.00$9,500,000.00View SEC Filing  
2/18/2015Adage Capital Partners Gp LlcMajor ShareholderBuy684,762$7.50$5,135,715.00View SEC Filing  
5/9/2014Richard J BermanDirectorSell14,530$2.63$38,213.90View SEC Filing  
3/31/2014Daniel O'connorCEOBuy3,333$3.00$9,999.00View SEC Filing  
10/24/2013Daniel O'connorCEOBuy13,500$4.00$54,000.00View SEC Filing  
10/24/2013Mark J RosenblumCFOBuy12,000$4.00$48,000.00View SEC Filing  
10/24/2013Robert PetitInsiderBuy12,800$4.00$51,200.00View SEC Filing  
10/24/2013Roni AppelDirectorBuy12,500$4.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Advaxis (NASDAQ:ADXS)
DateHeadline
biz.yahoo.com logoADVAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ADXS)
biz.yahoo.com - August 23 at 8:39 PM
News IconAdvaxis, Inc. (NASDAQ:ADXS) Looks Like A Great Catalyst Pick - Street Register (NASDAQ:ADXS)
streetregister.com - August 23 at 9:16 AM
investornewswire.com logoWill Advaxis, Inc. (NASDAQ:ADXS) Hit $26 Price Target? - Investor Newswire (NASDAQ:ADXS)
www.investornewswire.com - August 21 at 8:06 AM
News IconPhRMA: 258 Vaccines in Clinical Development (NASDAQ:ADXS)
sciencebusiness.technewslit.com - August 20 at 8:03 AM
publicnow.com logoAdvaxis to Participate in Cervivor School (NASDAQ:ADXS)
www.publicnow.com - August 19 at 11:44 AM
streetinsider.com logoAdvaxis (ADXS) Reports $30M Direct Placement of Common Stock (NASDAQ:ADXS)
www.streetinsider.com - August 18 at 8:50 PM
News IconActive Stocks Need to Consider- Advaxis, Inc. (NASDAQ:ADXS ... - Seneca Globe (NASDAQ:ADXS)
www.senecaglobe.com - August 17 at 8:50 PM
biz.yahoo.com logoADVAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Financial Con (NASDAQ:ADXS)
biz.yahoo.com - August 16 at 8:38 PM
News IconBrixmor Property Group (NYSE:BRX) & Advaxis, Inc. (NASDAQ:ADXS) Trend Analysis Report - Money News (press release) (NASDAQ:ADXS)
www.newsismoney.com - August 13 at 3:19 PM
News IconHealthcare Stocks Lure Investment- Advaxis, Inc. (NASDAQ:ADXS ... - Seneca Globe (NASDAQ:ADXS)
www.senecaglobe.com - August 12 at 3:24 PM
streetinsider.com logoAdvaxis (ADXS) Says AXAL Met Phase 1 Primary Objective; Will Advance to Phase 2 (NASDAQ:ADXS)
www.streetinsider.com - August 11 at 9:11 PM
smarteranalyst.com logoCompany Update (NASDAQ:ADXS): Advaxis, Inc. Advances AXAL Into Second Stage of Phase 2 Clinical Study (NASDAQ:ADXS)
www.smarteranalyst.com - August 11 at 9:11 PM
smarteranalyst.com logoCompany Update (NASDAQ:ADXS): Advaxis, Inc. Advances AXAL Into Second Stage of Phase 2 Clinical Study - Smarter Analyst (NASDAQ:ADXS)
www.smarteranalyst.com - August 11 at 12:33 PM
publicnow.com logoAdvaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage (NASDAQ:ADXS)
www.publicnow.com - August 11 at 12:33 PM
fortune.com logoNotable Brokerage Recommendations: Advaxis, Inc. (NASDAQ:ADXS), AMN Healthcare Services, Inc. (NYSE:AHS) - Review Fortune (NASDAQ:ADXS)
reviewfortune.com - August 9 at 12:04 PM
News IconAdvaxis Inc (NASDAQ:ADXS) Forms Global Agreement with Amgen - Small Cap Exclusive (press release) (NASDAQ:ADXS)
smallcapexclusive.com - August 9 at 12:04 PM
istreetwire.com logo3 Notable Runners: Diamond Resorts International, Inc. (DRII), Advaxis, Inc. (ADXS), MannKind Corp. (MNKD) - iStreetWire (NASDAQ:ADXS)
istreetwire.com - August 8 at 8:06 AM
investornewswire.com logoStrong Sell Calls For Advaxis, Inc. (NASDAQ:ADXS) At 0 - Investor Newswire (NASDAQ:ADXS)
www.investornewswire.com - August 6 at 8:24 PM
News IconAnalyst Research and Ratings: Advaxis, Inc. (NASDAQ:ADXS), U.S. Silica Holdings, Inc. (NYSE:SLCA) - TWN (NASDAQ:ADXS)
thewellesleysnews.com - August 6 at 11:04 AM
News IconSecurities Analyst Recommendations: Advaxis, Inc. (NASDAQ:ADXS), Pfizer Inc. (NYSE:PFE) - TWN (NASDAQ:ADXS)
thewellesleysnews.com - August 6 at 11:04 AM
streetupdates.com logoAnalyst Rating Trends to Observe: Advaxis, Inc. (NASDAQ:ADXS) , Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Street Updates (NASDAQ:ADXS)
www.streetupdates.com - August 5 at 8:44 PM
News IconTrading the Biotech News: Advaxis, Inc. (NASDAQ:ADXS), Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - The Voice Registrar (NASDAQ:ADXS)
voiceregistrar.com - August 5 at 8:44 PM
smarteranalyst.com logoBarclays Bumps Up Price Target on Advaxis, Inc. (ADXS) in the Wake of Amgen Deal - Smarter Analyst (NASDAQ:ADXS)
www.smarteranalyst.com - August 5 at 8:44 PM
smarteranalyst.com logoBarclays Bumps Up Price Target on Advaxis, Inc. (ADXS) in the Wake of Amgen Deal (NASDAQ:ADXS)
www.smarteranalyst.com - August 4 at 9:02 PM
News IconAdvaxis, Inc. (NASDAQ:ADXS), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Are Top 2 Winners Of The Week for Members (NASDAQ:ADXS)
www.marketnewscall.com - August 4 at 11:51 AM
smarteranalyst.com logoHC Wainwright Weighs in on Advaxis, Inc (ADXS) Following Commercial Deal with Amgen (AMGN) - Smarter Analyst (NASDAQ:ADXS)
www.smarteranalyst.com - August 3 at 8:57 PM
fool.com logoWhy Advaxis, Inc. Shares Are Soaring 11% Again Today - Motley Fool (NASDAQ:ADXS)
www.fool.com - August 3 at 3:22 PM
fool.com logoWhy Advaxis, Inc. Shares Are Soaring 11% Again Today (NASDAQ:ADXS)
www.fool.com - August 3 at 1:31 PM
fortune.com logoIdentifying Analyst Ratings Summary To Consider: Advaxis, Inc. (NASDAQ:ADXS), Ariad Pharmaceuticals, Inc ... - Review Fortune (NASDAQ:ADXS)
reviewfortune.com - August 3 at 11:54 AM
streetupdates.com logoAnalysts Reviewing Stocks: Advaxis, Inc. (NASDAQ:ADXS) , Brookdale Senior Living Inc. (NYSE:BKD) - Street Updates (NASDAQ:ADXS)
www.streetupdates.com - August 3 at 11:54 AM
News IconAdvaxis, Inc. (NASDAQ:ADXS) & Amgen, Inc. (NASDAQ:AMGN) Stock's Buzzers - Money News (press release) (NASDAQ:ADXS)
www.newsismoney.com - August 3 at 11:54 AM
smarteranalyst.com logoStock Update (NASDAQ:ADXS): Advaxis, Inc. and Amgen Enter Global Cancer Immunotherapies Collaboration - Smarter Analyst (NASDAQ:ADXS)
www.smarteranalyst.com - August 2 at 3:20 PM
finance.yahoo.com logoAmgen And Advaxis Enter Global Cancer Immunotherapies Collaboration (NASDAQ:ADXS)
finance.yahoo.com - August 2 at 8:06 AM
ftsenews.co.uk logoAdvaxis, Inc. (ADXS) Updated Price Targets - FTSE News (NASDAQ:ADXS)
www.ftsenews.co.uk - August 1 at 8:06 AM
ftsenews.co.uk logoBrokers Issue Average Price Target Of 23.82 On Advaxis, Inc. (ADXS ... - FTSE News (NASDAQ:ADXS)
www.ftsenews.co.uk - July 30 at 3:25 PM
smarteranalyst.com logoStock Update (NASDAQ:ADXS): Advaxis, Inc. Announces Completion of Second Dose-Escalation Cohort for Phase 1/2 ... - Smarter Analyst (NASDAQ:ADXS)
www.smarteranalyst.com - July 26 at 12:23 PM
publicnow.com logoPhase 1/2 Combination Trial of AXAL and Durvalumab Completes Second Dose-Escalation Cohort (NASDAQ:ADXS)
www.publicnow.com - July 26 at 8:18 AM
4-traders.com logoAdvaxis : AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients (NASDAQ:ADXS)
www.4-traders.com - July 25 at 8:58 PM
investornewswire.com logoIs $25 Price Target Attainable For Advaxis, Inc. (NASDAQ:ADXS)? - Investor Newswire (NASDAQ:ADXS)
www.investornewswire.com - July 24 at 8:07 AM
News IconEquity Roundup: Stock Performance Focus on Advaxis, Inc. (NASDAQ:ADXS) - Press Telegraph (NASDAQ:ADXS)
presstelegraph.com - July 23 at 3:20 PM
News IconStock Displaying Signs of a Downtrend: Advaxis, Inc. (NASDAQ:ADXS) - Press Telegraph (NASDAQ:ADXS)
presstelegraph.com - July 23 at 3:20 PM
streetupdates.com logoAnalyst Rating Trends to Observe: Community Health Systems, Inc. (NYSE:CYH) , Advaxis, Inc. (NASDAQ:ADXS) - Street Updates (NASDAQ:ADXS)
www.streetupdates.com - July 22 at 3:18 PM
News IconTrading Examination: Performance check on Advaxis, Inc. (NASDAQ:ADXS) - TGP (NASDAQ:ADXS)
telanaganapress.com - July 22 at 3:18 PM
biz.yahoo.com logoADVAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (NASDAQ:ADXS)
biz.yahoo.com - July 22 at 7:31 AM
News IconChecking in on Stock Volatility for: Advaxis, Inc. (NASDAQ:ADXS) - Engelwood Daily (NASDAQ:ADXS)
www.engelwooddaily.com - July 21 at 3:21 PM
News IconAdvaxis, Inc. (NASDAQ:ADXS): Share Synopsis and Trading Review - Press Telegraph (NASDAQ:ADXS)
presstelegraph.com - July 21 at 3:21 PM
smarteranalyst.com logoStock Update (NASDAQ:ADXS): Advaxis, Inc.'s AXAL Receives Fast Track Designation by the FDA as Adjuvant ... - Smarter Analyst (NASDAQ:ADXS)
www.smarteranalyst.com - July 21 at 3:21 PM
globenewswire.com logoAdvaxis’ AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients (NASDAQ:ADXS)
globenewswire.com - July 21 at 11:57 AM
streetinsider.com logoAdvaxis (ADXS) Granted FDA Fast Track Designation for AXAL (NASDAQ:ADXS)
www.streetinsider.com - July 21 at 11:57 AM
News IconEMA committee classifies Advaxis’ Lm immunotherapy candidate, AXAL as advanced-therapy medicinal product (NASDAQ:ADXS)
pharmabiz.com - July 20 at 10:19 PM

Social

Advaxis (NASDAQ:ADXS) Chart for Tuesday, August, 23, 2016


Last Updated on 8/23/2016 by MarketBeat.com Staff